7182-08-3

Basic information

• Product Name: 1-MORPHOLINO-1-CYCLOHEPTENE
• Synonyms: 1-MORPHOLINO-1-CYCLOHEPTENE;1-MORPHOLINO-1-CYCLOHEPTENE 95%;4-(cyclohepten-1-yl)morpholine
• CAS NO: 7182-08-3
• Molecular Formula: C₁₁H₁₉NO
• Molecular Weight: 181.27
• Mol File: 7182-08-3.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 108 °C/4 mmHg(lit.)
• Flash Point: 94 °C
• Appearance: /
• Density: 0.994 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.00158mmHg at 25°C
• Refractive Index: n20/D 1.509(lit.)
• CAS DataBase Reference: 1-MORPHOLINO-1-CYCLOHEPTENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-MORPHOLINO-1-CYCLOHEPTENE(7182-08-3)
• EPA Substance Registry System: 1-MORPHOLINO-1-CYCLOHEPTENE(7182-08-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 7182-08-3(Hazardous Substances Data)

Usage

Type of compound

Bicyclic organic compound

Containing rings

Morpholine ring and cycloheptene ring

Use in organic synthesis

1-MORPHOLINO-1-CYCLOHEPTENE has been studied for its potential use in organic synthesis due to its unique structure.

Pharmaceutical applications

The compound has been investigated for its potential use in pharmaceutical applications, as a building block for the synthesis of biologically active molecules.

Ligand in metal-catalyzed reactions

1-MORPHOLINO-1-CYCLOHEPTENE has been studied for its ability to act as a ligand in metal-catalyzed reactions, further expanding its potential applications in the field.

Development of new chemical reactions

The unique structure of 1-MORPHOLINO-1-CYCLOHEPTENE makes it a valuable tool for the development of new chemical reactions.

Creation of pharmaceutical compounds

The compound is also valuable in the development of new pharmaceutical compounds, as it can be used as a building block for the synthesis of biologically active molecules.

InChI:InChI=1/C11H19NO/c1-2-4-6-11(5-3-1)12-7-9-13-10-8-12/h5H,1-4,6-10H2

Upstream product

• 110-91-8 morpholine 
• 502-42-1 cycloheptanone 

Downstream Products

• 124570-81-6 1α,6α,7α-7-morpholino-N-phenyl-7-succinimido-bicyclo<4.1.0>heptane-1-carboxamide 
• 125284-00-6 4a,6,7,8,9,9a-Hexahydro-4a-morpholino-1,4-diphenyl-5H-cycloheptapyridazine 
• 68629-75-4 6,7,8,9-Tetrahydro-1,4-diphenyl-5H-cycloheptapyridazine 
• 4436-63-9 6,7,8,9-Tetrahydro-5H-cyclohepta[d]pyrimidine 
• 310902-11-5 2-[2-(3-methoxyphenyl)-2-oxoethyl]-cycloheptanone 
• 310902-38-6 3-(3-methoxyphenyl)-4,5,6,7,8,9-hexahydrocyclohepta[b]pyran-2(3H)-one 
• 132452-19-8 2-[(2-bromophenyl)methyl]cycloheptanone 
• 132452-95-0 Benzyl-[2-(2-bromo-benzyl)-cyclohept-(E)-ylidene]-amine 
• 138642-67-8 2-Ethyl-4-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethoxy]-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine 
• 18014-84-1 4-(2-phenyl-octahydro-cyclohepta[b]furan-8a-yl)-morpholine 
• 80618-59-3 2-morpholino-N-phenyl-1-cycloheptene-1-carboxamide 
• 59847-24-4 (2-morpholino-1-cyclohepten-1-yl)-phenyl-methanone 
• 59847-22-2 benzoyloxy-(2-morpholin-4-yl-cyclohept-2-enylidene)-phenyl-methane 

Relevant articles and documents

-

-

Discovery of quinolone derivatives as antimycobacterial agents

Tuberculosis (TB), an infectious disease caused byMycobacterium tuberculosis(M. tuberculosis), is an important public health issue. Current first-line drugs administered to TB patients have been in use for over 40 years, whereas second-line drugs display strong side effects and poor compliance. Additionally, designing effective regimens to treat patients infected with multi- and extremely-drug-resistant (MDR and XDR) strains of TB is challenging. In this report, we screened our compound library and identified compound1with antituberculosis activity and a minimal inhibitory concentration (MIC) againstM. tuberculosisof 20 μg mL?1. Structure optimization and the structure-activity relationship of1as the lead compound enabled the design and synthesis of a series of quinolone derivatives,6a1-6a2,6b1-6b36,6c1,6d1-6d14,7a1-7a2,7b1-7b2,7c1,8a1-8a5,9a1-9a4and10a1-10a6. These compounds were evaluatedin vitrofor anti-tubercular activity against theM. tuberculosisH37Rv strain. Among them, compounds6b6,6b12and6b21exhibited MIC values in the range of 1.2-3 μg mL?1and showed excellent activity against the tested MDR-TB strain (MIC: 3, 2.9 and 0.9 μg mL?1, respectively). All three compounds were non-toxic toward A549 and Vero cells (>100 and >50 μg mL?1, respectively). In addition, an antibacterial spectrum test carried out using compound6b21showed that this compound specifically inhibitsM. tuberculosis. These can serve as a new starting point for the development of anti-TB agents with therapeutic potential.

The hit-to-lead optimization of 1,2,3,4,4a,9a-hexahydro-1H-xanthenes as glucocorticoid receptor antagonists

The structure-activity relationship (SAR) study of a 1,2,3,4,4a,9a- hexahydro-1H-xanthene series of selective, human glucocorticoid receptor α (hGRα) antagonists is reported. Compounds were screened using hydroxyapatite-based GR binding and MMTV-Luc co-transfection reporter gene assays. Four different regions of the scaffold were modified to assess the effects on hGRα antagonism and related potency. Compound 8d exhibits an 8-fold better bioactivity than the original hit 1a, as well as an improved chemical stability, which make it a promising lead for the subsequent optimization.